Glucagon-like peptide-1 receptor agonists and alcohol use disorders: an emerging unexpected beneficial effect
Scheen AJ
Diabetes Obes Metab. Pub. online 13 May 2025.
Leggi
One-hour plasma glucose predicts the progression from normal glucose tolerance to prediabetes
Abdul-Ghani M, Abu-Farha M, Abdul-Ghani T, et al.
Diabetes Care. 2025:dc242832.
Leggi
Tirzepatide and health-related quality of life in adults with obesity or overweight: results from the SURMOUNT-3 phase 3 randomized trial
Gibble TH, Cao D, Forrester T, et al.
Diabetes Obes Metab. Pub. online 14 May 2025.
Leggi
Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism
Henriksen K, Rufer C, Title AC, et al.
Diabetologia. Pub. online 15 May 2025.
Leggi
Assessing the accuracy of continuous glucose monitoring metrics: the role of missing data and imputation strategies
Cichosz SL, Kronborg T, Hangaard S, et al.
Diabetes Technol Ther. Pub. online 14 May 2025.
Abstract
Leggi
Stroke incidence evolution in people with newly diagnosed diabetes and impaired glucose tolerance: a 34-year follow-up of the Da Qing Diabetes Study
Chen Y, Wang J, Feng X, et al.
Diabetes Care. 2025:dc242675.
Leggi
Effect of intermittent fasting on obesity and metabolic indices in patients with metabolic syndrome: a systematic review and meta analysis
Zhang S, Sun B, Sun L, et al.
BMC Endocr Disord. 2025;25(1):130.
Leggi
The effectiveness of lifestyle interventions in reducing cardiovascular risk and risk factors in people with prediabetes: a systematic review and meta-analysis
Demissie GD, Birungi J, Shrestha A, et al.
Nutr Metab Cardiovasc Dis. Pub. online 14 May 2025.
Leggi
Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study
Cardoso P, Young KG, Hopkins R, et al.
Diabetes Obes Metab.Pub. online 16 May 2025.
Leggi
PROGETTO E-GOAL – L’inerzia clinica nel diabete: la soluzione dall’intelligenza artificiale? – Roma, 17 maggio 2025
Carissimi, siamo lieti di condividere l’ultima tappa del progetto “E-GOAL - L’inerzia clinica nel diabete: la soluzione dall’intelligenza artificiale?”. Ci ritroveremo domani a Roma per un evento di approfondimento e per la presentazione dei risultati dell’iniziativa. Si ringrazia per il contributo non condizionante di Novo Nordisk. Grazie per l’attenzione e…
Leggi